Compare

Actuate Therapeutics, Inc. vs Exicure, Inc. vs Biovie Inc. vs Chemomab Therapeutics Ltd.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal year	Actuate Therapeutics, Inc. ACTU	Exicure, Inc. XCUR	Biovie Inc. BIVI	Chemomab Therapeutics Ltd. CMMB
Year ended	2025-12-31	2025-12-31	2026-06-30	2025-12-31
Revenue	n/a	$0	n/a	n/a
Revenue growth (YoY)	n/a	-100.0%	n/a	n/a
Gross margin	n/a	n/a	n/a	n/a
Operating margin	n/a	n/a	n/a	n/a
Net margin	n/a	n/a	n/a	n/a
Net income	-$22.23M	-$4.95M	-$22.07M	-$8.99M
EPS (Diluted)	-$1.06	-$0.79	-$3.05	$0.018
Operating cash flow	-$19.21M	-$8.55M	-$19.02M	-$11.13M
Free cash flow	n/a	-$8.56M	n/a	-$11.13M
Cash & equivalents	$13.16M	n/a	$8.98M	$7.56M
Total assets	$14.04M	$14.04M	$14.25M	$13.81M
Total liabilities	$6.11M	$10.12M	$3.98M	$1.48M
Shareholders' equity	$7.92M	$3.93M	$10.27M	$12.33M
Return on year-end equity	-280.5%	-126.0%	-214.9%	-72.9%
Shares outstanding	23.25M	6.37M	7.54M	n/a

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal year	Actuate Therapeutics, Inc.	Exicure, Inc.	Biovie Inc.	Chemomab Therapeutics Ltd.
Latest	n/a	$0 Ended 2025-12-31	n/a	n/a
1 year earlier	n/a	$500.0K Ended 2024-12-31	n/a	n/a
2 years earlier	n/a	$0 Ended 2023-12-31	n/a	n/a
3 years earlier	n/a	$28.83M Ended 2022-12-31	n/a	n/a
4 years earlier	n/a	-$483.0K Ended 2021-12-31	n/a	n/a